Pear Therapeutics and Prescryptive Health Announce Formulary Coverage for Prescription Digital Therapeutics reSET® & reSET-O® for the Treatment of Substance and Opioid Use Disorders
By
Staff
2 seconds ago
Prescryptive Health, a health intelligence platform focused on improving the prescription drug market and the pharmacy experience, teams with Pear to make innovative prescription digital therapeutics (PDTs) accessible to its members in recovery.
Prescryptive Health will offer and administer Pear’s reSET® and reSET-O® through its digital platform as a covered standard pharmacy benefit for people with substance use disorder or opioid use disorder.
BOSTON & SAN FRANCISCO & REDMOND, Wash.–(BUSINESS WIRE)–Pear Therapeutics, Inc. and Prescryptive Health today announced that Prescryptive, the first health intelligence platform, will offer and administer benefit coverage for reSET® and reSET-O®, the first two prescription digital therapeutics (PDTs) to receive authoriza
Company adds a leading national Integrated Delivery Network (IDN) as a strategic investor.
The financing supports Pear’s continued efforts to expand patient access for its portfolio of Prescription Digital Therapeutics (PDTs), including reSET®, reSET-O® and Somryst® treating addiction and insomnia conditions, respectively.
BOSTON & SAN FRANCISCO–(BUSINESS WIRE)–Pear Therapeutics, Inc., (“Pear” or the “Company”) today announced the second closing of its Series D financing. The second closing included a leading national Integrated Delivery Network (IDN) as a new strategic investor. The national IDN is investing $20 million, bringing the total Series D investment to $100 million.
“Pear is pleased to add one of America’s leading health care providers and health plans to our distinguished list of investors as we continue to expand patient access to our FDA-authorized digital therapeutics,” said Corey McCann, M.D., Ph.D., President and CEO of Pear Therapeutics.
Pear Therapeutics Announces Publication of Economic Analysis Showing Cost-Effectiveness of reSET-O® in Treating Opioid Use Disorder digitalmedianet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitalmedianet.com Daily Mail and Mail on Sunday newspapers.
etectRx Announces Agreement to Advance Digital Sensors for Medication Adherence in Combination with Prescription Digital Therapeutics
News provided by
Share this article
Share this article
GAINESVILLE, Fla., Jan. 14, 2021 /PRNewswire/ Digital health company, etectRx, Inc., announced today that it has entered into an agreement with Pear Therapeutics, Inc. to develop up to two product candidates in the Central Nervous System (CNS) space combining Prescription Digital Therapeutics (PDTs) and adherence sensors. The collaboration is the first of its kind to explore the use of digital pill solutions with PDTs. This collaboration between etectRx and Pear Therapeutics comes at a critical time for the mental health field, an area that is in dire need of immediate solutions, said Valerie Sullivan, president and CEO of etectRx. Our goal for this collaboration is to bring concrete solutions to those who need it.
Share
The life science world has continued to deepen its interest in the digital space. While the mainstream life science news of the year was research on the coronavirus vaccine, when it came to digital the industries efforts were more varied. We saw new partnerships between pharma and digital health around topics such as respiration health, cardiovascular conditions and real-world data.
This year we’ve also seen a number of new digital therapeutics on the market. In fact, in April the FDA released new guidance on digital health devices for treating psychiatric disorders that waives several regulatory requirements – such as the need to submit a 510(k) premarket notification – for the duration of the COVID-19 emergency. During this period we saw both Pear Therapeutics and Akili Interactive Labs take advantage of this early release.